Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 19, 2025
Efficacy of xanomeline and xanomeline trospium in the treatment of cognitive impairment: A systematic review of preclinical and clinical trialsKyle Valentino, Bianca Shen, Bethany Waisman, et al.Schizophrenia Research|January 9, 2026
Association between negative symptoms and health-related quality of life and functional outcomes in persons with schizophrenia: A systematic reviewAllyssa Chan, Andy Lu, Trisha Menon, et al.Neurology and Therapy|April 2, 2025
Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative ReviewJuliana West, Maggie Li, Sabrina Wong, et al.Journal of Affective Disorders|April 24, 2025
The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic ReviewMorgan C H Cheng, Christine E Dri, Hana Ballum, et al.Journal of Psychiatric Research|February 16, 2025
The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic reviewKyle Valentino, Kayla M Teopiz, William Cheung, et al.Expert Opinion on Emerging Drugs|January 10, 2025
Seltorexant for major depressive disorderKyle Valentino, Kayla M Teopiz, Sabrina Wong, et al.CNS Spectrums|June 2, 2025
A systematic review of anti-suicidal effects of sedative-hypnotics and cognitive behavioral therapy for insomniaKyle Valentino, Kayla Teopiz, Sabrina Wong, et al.CNS Spectrums|December 27, 2024
Anatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic reviewKyle Valentino, Kayla M Teopiz, Angela T H Kwan, et al.Therapeutic Advances in Psychopharmacology|December 25, 2025
Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic reviewSerene Lee, Liyang Yin, Kayla M Teopiz, et al.Expert Opinion on Therapeutic Targets|April 29, 2025
The sigma-1 receptor: a mechanistically-informed therapeutic target for antidepressantsNaomi Xiao, Liyang Yin, Kayla M Teopiz, et al.Pageof 2